J Pharmacol Exp Ther 319, 1355-1365, (2006). Katnik, C., Guerrero, W. R., Pennypacker, K. R., Herrera, Y., & Cuevas, J. View abstract in PubMed Post navigationPreviousPrevious post:The expression and functional characterization of sigma-1 receptors in breast cancer cell lines.NextNext post:Interactions between 3,4- methylenedioxymethamphetamine and sigma-1 receptors.Related PostsAnavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical TrialSeptember 10, 2020Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Parkinson’s DiseaseAugust 19, 2020Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)July 6, 2020Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Rett SyndromeJuly 1, 2020
Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical TrialSeptember 10, 2020
Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Parkinson’s DiseaseAugust 19, 2020
Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)July 6, 2020
Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Rett SyndromeJuly 1, 2020
